pemigatinib + docetaxel

**Pemigatinib + docetaxel** is a combination regimen of two pharmaceutical agents: **pemigatinib**, an oral, potent, selective inhibitor of fibroblast growth factor receptor (FGFR) 1-3, and **docetaxel**, an intravenous taxane class chemotherapeutic that stabilizes microtubules and inhibits cell division. Pemigatinib targets abnormal FGFR signaling, which is implicated in various cancers with FGFR alterations, while docetaxel impedes mitosis by binding to tubulin. This combination has been studied in advanced solid tumors, including cholangiocarcinoma and other FGFR-altered malignancies, primarily in early phase clinical studies to evaluate safety, tolerability, pharmacodynamics, and preliminary efficacy. The combination aims to enhance antitumor activity by dual inhibition of cell signaling and cell division pathways[1][5][7].